Rapid and Durable Protection Against Ebola Virus With New Vaccine Regimens

Scanning electron micrograph of Ebola virus budding from a cell (African green monkey kidney epithelial cell line). Credit: NIAID
Scanning electron micrograph of Ebola virus budding from a cell (African green monkey kidney epithelial cell line).
Credit: NIAID
NIH Scientists and Collaborators Report Positive Results in Monkeys

One shot of an experimental vaccine made from two Ebola virus gene segments incorporated into a chimpanzee cold virus vector (called chimp adenovirus type 3 or ChAd3) protected all four macaque monkeys exposed to high levels of Ebola virus 5 weeks after inoculation, report National Institutes of Health (NIH) scientists and their collaborators. The ability of the ChAd3 Ebola virus vaccine to elicit rapid protection in monkeys is notable as the world health community battles an ongoing Ebola virus disease outbreak in West Africa. While the protective effects of the single shot waned over time, two out of four inoculated animals were protected when challenged with Ebola virus 10 months after vaccination.

The research team, headed by Nancy J. Sullivan, Ph.D., of the National Institute of Allergy and Infectious Diseases Vaccine Research Center, also demonstrated increased levels of durable protection using an additional vaccine. They inoculated four macaques first with the ChAd3 Ebola vaccine, then 8 weeks later with a booster vaccine containing Ebola virus gene segments incorporated into a different vector (a poxvirus). Ten months after the initial inoculation, four out of four animals that received both shots were fully protected from infection with high doses of Ebola virus, demonstrating that the prime-boost regimen resulted in durable protection.

Read more . .

 

The Latest on: Ebola

[google_news title=”” keyword=”Ebola” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]

via Google News

 

See Also

The Latest on: Ebola

via  Bing News

 

.

What's Your Reaction?
Don't Like it!
0
I Like it!
0
Scroll To Top